Overvalued? The future carries much more weight than the past in valuing any stock, but especially biotechs. In light of the numbers, I don't think these billion-dollar biotechs are overvalued at all. In fact, I think they're both still undervalued considering their potential.
Since Pharmacyclics and Sarepta have yet to receive approval for their lead drugs, we do need to consider the possibility that bumps along the road could occur. However, both companies seem to have the odds in their favor at this point. - insider monkey
well, there is more in the pipeline as we all know. If other things take off, specially auto immune, this company will surely grow into a major biotech. Ibrutinib's outstanding performance will be more and more recognized now and If you read between all messages and releases you can guess that things will get to the market much earlier than expected. For sure, this months short return to 70 was a "gift "as Truth said.
IMO, this was the very last chance to get in cheap. This will get back now to where it was and might even reach new highs soon. As we said beginning of 2013, this will be an exiting year guys